Cedric Francois, Apellis CEO (Apellis)
Apellis joins the growing number of biopharmas scrapping a failed Covid-19 program after an early flop
The global pandemic set off a frenzy of R&D activity as biotechs around the world scrambled to see if they could come up with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
